Exposure and response prevention therapy augmented with naltrexone in kleptomania: a controlled case study using galvanic skin response for monitoring.
CBT
exposure and response prevention
galvanic skin response
kleptomania
Journal
Behavioural and cognitive psychotherapy
ISSN: 1469-1833
Titre abrégé: Behav Cogn Psychother
Pays: United States
ID NLM: 9418292
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
pubmed:
22
3
2019
medline:
26
11
2019
entrez:
22
3
2019
Statut:
ppublish
Résumé
Kleptomania is a disease that shares features with obsessive compulsive spectrum disorders (OCD) and with substance abuse disorders (SAD). This is underlined by therapeutic approaches in kleptomania ranging from cognitive behavioural therapy and selective serotonin reuptake inhibitors that are effective in OCD, and opioid antagonists that are currently being used in SAD. However, almost no literature exists about exposure and response prevention (ERP) therapy in kleptomania. Furthermore, there is a clear lack of objective markers that would allow a therapeutic monitoring. To show the effectiveness of ERP therapy in kleptomania in a single case report. An ERP therapy under real-world conditions and later augmentation with the opioid antagonist naltrexone is described. Continuous measurements of galvanic skin response (GSR) before, during and after therapy sessions are reported in association with changes of the Kleptomania Symptom Assessment Scale (KSAS) self-questionnaire. While KSAS scores showed a clear treatment response to ERP sessions, the GSR was significantly lower during ERP treatment in comparison with baseline measures. However, during augmentation with naltrexone, GSR measures increased again and clinical severity did not further improve. This case shows the possible usefulness of ERP-like approaches and therapy monitoring using electrophysiological markers of arousal for individualized treatment in kleptomania.
Sections du résumé
BACKGROUND
BACKGROUND
Kleptomania is a disease that shares features with obsessive compulsive spectrum disorders (OCD) and with substance abuse disorders (SAD). This is underlined by therapeutic approaches in kleptomania ranging from cognitive behavioural therapy and selective serotonin reuptake inhibitors that are effective in OCD, and opioid antagonists that are currently being used in SAD. However, almost no literature exists about exposure and response prevention (ERP) therapy in kleptomania. Furthermore, there is a clear lack of objective markers that would allow a therapeutic monitoring.
AIM
OBJECTIVE
To show the effectiveness of ERP therapy in kleptomania in a single case report.
METHOD
METHODS
An ERP therapy under real-world conditions and later augmentation with the opioid antagonist naltrexone is described. Continuous measurements of galvanic skin response (GSR) before, during and after therapy sessions are reported in association with changes of the Kleptomania Symptom Assessment Scale (KSAS) self-questionnaire.
RESULTS
RESULTS
While KSAS scores showed a clear treatment response to ERP sessions, the GSR was significantly lower during ERP treatment in comparison with baseline measures. However, during augmentation with naltrexone, GSR measures increased again and clinical severity did not further improve.
CONCLUSIONS
CONCLUSIONS
This case shows the possible usefulness of ERP-like approaches and therapy monitoring using electrophysiological markers of arousal for individualized treatment in kleptomania.
Identifiants
pubmed: 30894239
pii: S1352465819000213
doi: 10.1017/S1352465819000213
doi:
Substances chimiques
Narcotic Antagonists
0
Naltrexone
5S6W795CQM
Types de publication
Case Reports
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM